AxoGen (NASDAQ:AXGN) Reaches New 1-Year High – Here’s Why

26 Aug 2026, 18:41 by Sarita Garza · The Markets Daily

AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $51.56 and last traded at $51.53, with a volume of 359011 shares changing hands. The stock had previously closed at $49.93.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AXGN shares. Canaccord Genuity Group raised their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Wells Fargo & Company raised their price objective on shares of AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Jefferies Financial Group reissued a “buy” rating and set a $55.00 target price on shares of AxoGen in a research note on Wednesday, July 29th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $48.00 price target on shares of AxoGen in a report on Wednesday, April 29th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.56.

Get Our Latest Report on AxoGen

AxoGen Stock Up 3.3%

The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The firm’s 50-day simple moving average is $44.35 and its two-hundred day simple moving average is $39.19. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of -75.88 and a beta of 1.11.

AxoGen (NASDAQ:AXGN – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.12. The company had revenue of $69.73 million during the quarter, compared to the consensus estimate of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Sell-side analysts predict that AxoGen, Inc. will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling at AxoGen

In other news, EVP Marc A. Began sold 67,500 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $47.34, for a total value of $3,195,450.00. Following the completion of the transaction, the executive vice president owned 50,135 shares in the company, valued at $2,373,390.90. This trade represents a 57.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Mcbride Wendell sold 13,353 shares of AxoGen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the transaction, the director directly owned 107,976 shares of the company’s stock, valued at $5,228,197.92. This trade represents a 11.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 95,003 shares of company stock valued at $4,482,997. Insiders own 2.44% of the company’s stock.

Hedge Funds Weigh In On AxoGen

Several hedge funds have recently bought and sold shares of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of AxoGen in the second quarter valued at $954,000. California State Teachers Retirement System increased its position in AxoGen by 4,400.3% during the 2nd quarter. California State Teachers Retirement System now owns 2,661,006 shares of the medical equipment provider’s stock worth $122,912,000 after purchasing an additional 2,601,877 shares in the last quarter. Nykredit A S acquired a new position in AxoGen in the 2nd quarter valued at about $30,000. Aubrey Capital Management Ltd raised its stake in AxoGen by 13.4% in the 2nd quarter. Aubrey Capital Management Ltd now owns 98,700 shares of the medical equipment provider’s stock valued at $4,560,000 after purchasing an additional 11,700 shares during the last quarter. Finally, F&V Capital Management LLC lifted its holdings in AxoGen by 4.1% in the 2nd quarter. F&V Capital Management LLC now owns 184,385 shares of the medical equipment provider’s stock valued at $8,517,000 after purchasing an additional 7,210 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

(Get Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.